Pharma Q4 Results Preview: J&J, Novartis, Celgene, Biogen & AbbVie

 
• By Kevin Grogan, Joseph Haas, Mandy Jackson, Jessica Merrill, and Sten Stovall

Novartis expected to give Joe Jimenez a good farewell gift; AbbVie says it is not planning major M&A to focus on risankizumab and upadacitinib, but Celgene is on the hunt for deals – will Juno be its next big buy?

4th quarter computer key on key board

More from Earnings

More from Business